Topical Palm Tocotrienols on Blemish-prone Skin

November 27, 2023 updated by: Goh Choon Fu, Universiti Sains Malaysia

A Randomised Double-blind Placebo-controlled Study on the Effects of Topical Palm Tocotrienols on Blemish-prone Skin

A single-center, double-blind, randomised, placebo-controlled parallel-group study.

Selected subjects will be randomised into active and control groups in a ratio of 1:1. Investigational products assigned will be applied on the facial skin as part of daily skin care routine. The effects will be observed during the 12-weeks of use.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

5

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Pulau Pinang, Malaysia, 11800
        • School of Pharmaceutical Sciences, Universiti Sains Malaysia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Healthy individuals, aged 18 years and above
  2. Fitzpatrick skin type II to IV
  3. Blemish-prone skin with acne of severity grade 2 or 3 based on Comprehensive Acne Severity Scale (CASS)

Exclusion Criteria:

  1. Has a history of chronic drug or alcohol abuse
  2. Is a current smoker
  3. History of severe allergic reactions to topical products or vitamin E
  4. Participant with severe and uncontrollable comorbidities (including but not limited to e.g. diabetes, hypertension, kidney failure)
  5. Pregnant, breastfeeding, or planning pregnancy
  6. Participant with known skin conditions (including but not limited to e.g. sensitive skin, eczema and diseased skin e.g. contact dermatitis), uncontrolled medical conditions, or any other condition that could interfere with the study evaluations or increase risk to the participant (such as polycystic ovary syndrome and contact dermatitis)
  7. Participant with compromised/broken skin, tattoos, scarring, excessive hair growth, very uneven skin tone, or other conditions that would interfere with evaluations or increase risk
  8. Participation in another study within 4 weeks of screening visit
  9. Has severe acne or acne conglobata
  10. Use of systemic treatment for acne such as isotretinoin, contraceptive pills, or spironolactone within 4 weeks of screening visit
  11. Use of topical treatments like antibiotics, corticosteroids, benzoyl peroxide, azelaic acid, salicylic acid, alpha hydroxy acids (AHAs), vitamins A (retinol) or C (ascorbic acid) or their analogs or derivatives and other anti-inflammatory drugs within 2 weeks of screening visit
  12. Use of scrub, alpha-hydroxy acid (AHA), skin irritant products in the 2 days before study treatment start
  13. Participant with active bacterial/fungal/viral skin infections or susceptibility to such infections within 2 weeks of Screening visit
  14. Use oral antibiotics

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Serum containing 1.5 % w/w of palm-oil derived vitamin E concentrate
Apply on the face twice a day
Placebo Comparator: Serum (placebo)
Apply on the face twice a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants with at least 50% reduction in numbers of acne lesion or at least 2 grade improvement according to CASS from baseline
Time Frame: 18 Week
Acne lesion count
18 Week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percent change from baseline in global face total lesion count.
Time Frame: 18 Week
Acne lesion count
18 Week
Acne lesion counts for the total global face and total lesion counts
Time Frame: 18 Week
Acne lesion count
18 Week
CASS assessment
Time Frame: 18 Week
Comprehensive Acne Severity Scale (CASS)
18 Week
Survey (CADI)
Time Frame: 18 Week
The Cardiff Acne Disability Index 2021
18 Week
The percent change from baseline in sebum, skin pH, hydration and erythema index
Time Frame: 18 Week
Skin probe
18 Week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Choon Fu Goh, PhD, Universiti Sains Malaysia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 15, 2023

Primary Completion (Actual)

November 16, 2023

Study Completion (Actual)

November 16, 2023

Study Registration Dates

First Submitted

February 10, 2023

First Submitted That Met QC Criteria

March 4, 2023

First Posted (Actual)

March 6, 2023

Study Record Updates

Last Update Posted (Actual)

November 28, 2023

Last Update Submitted That Met QC Criteria

November 27, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • MA-T3-T3

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe